FANCF Methylation and Ovarian Cancer Outcomes
Author Information
Author(s): Lim S L, Smith P, Syed N, Coens C, Wong H, van der Burg M, Szlosarek P, Crook T, Green J A
Primary Institution: University of Liverpool
Hypothesis
Is methylation-dependent transcriptional silencing of FANCF a determinant of clinical response and outcome to platinum-based chemotherapy in ovarian cancer?
Conclusion
The study found that FANCF methylation is not a major feature of chemonaive ovarian cancers and does not significantly impact response to platinum-based chemotherapy.
Supporting Evidence
- FANCF methylation was detected in 9.4% of ovarian cancer cases.
- Progression-free survival was significantly better in unmethylated cases.
- FANCF methylation was not associated with overall survival.
Takeaway
This study looked at how a gene called FANCF might affect how well ovarian cancer patients respond to chemotherapy. It found that changes in this gene didn't really help predict how patients would do.
Methodology
Methylation status of FANCF was assessed using methylation-sensitive PCR in ovarian cancer cell lines and tissue samples from patients on a clinical trial.
Limitations
The study had a small sample size and limited categories for response assessment.
Participant Demographics
Patients predominantly had stage III and IV ovarian cancer.
Statistical Information
P-Value
0.0016
Confidence Interval
95% CI: 1.54–8.54
Statistical Significance
p=0.0016
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website